Merck's Strategic Pivot: Building a $70 Billion Pipeline Beyond Keytruda

The core challenge for Merck is a looming cliff. Its flagship drug, Keytruda, is projected to peak at almost $32.7 billion in 2026. After that, sales are expected to decline sharply, with exclusivity set to expire in 2028. Analysts forecast a steep drop to just over $7 billion by 2032. This isn't a minor slowdown; it's the erosion of a revenue engine that pulled in almost $29.5 billion last year, representing nearly half of the company's total sales.

To navigate this, CEO Rob Davis has set a clear, ambitious target: a $70 billion commercial opportunity by mid-2030. This figure represents a significant increase of $20 billion from last year, explicitly aimed at offsetting the impending patent loss. The thesis is one of structural resilience through a multi-pronged pivot.

The foundation for this target is a robust pipeline. Merck points to 20 growth drivers and 80 Phase III studies in progress. Crucially, approximately 70% of the $70 billion target is expected to stem from 10 key assets with blockbuster potential. This focus on a concentrated set of high-value candidates provides a credible path to growth, moving beyond reliance on a single product.

The company's proactive move with Keytruda Qlex-a subcutaneous version approved for 38 solid tumor indications-illustrates this strategy in action. While not a panacea, it aims to soften the blow by extending market share and adding new revenue streams post-2028. Yet the $70 billion target is a forward-looking bet on the successful clinical and commercial execution of its entire pipeline. The path is clear, but the execution required to deliver on it will define Merck's next chapter.

The Subcutaneous Pivot: Qlex as a Keytruda Lifeline

Merck's launch of Keytruda Qlex is a masterclass in defensive strategy. This subcutaneous formulation, approved for 38 solid tumor indications, reduces administration time from a half-hour infusion to just one or two minutes. It is the first and only subcutaneous PD-1 inhibitor with such a broad footprint, a move designed to lock in patients and clinicians before the patent cliff hits.

The near-term impact is expected to be rapid and decisive. Analysts forecast Qlex sales will rise steadily, hitting more than $7 billion by 2032. More importantly, it fundamentally alters the revenue trajectory. By factoring in Qlex, the anticipated decline in Keytruda sales post-2028 appears far less severe. As one consultant noted, the combined total for the two versions "doesn't even look like a sharp decline anymore." This isn't about replacing the original's peak; it's about extending its commercial life and softening the blow.

The strategic brilliance lies in its payer and patient appeal. In an era of intense competition, Qlex makes it unlikely patients will switch back to longer intravenous infusions offered by biosimilars. It provides a clear, convenient alternative that improves the healthcare experience. This is a sensible, market-friendly tactic to maintain dominance against a new generation of rivals. Bristol Myers Squibb's Opdivo Qvantig was approved in December 2024, and Roche's Tecentriq SC has already entered European markets. Merck is racing to secure its position in this subcutaneous shift, using Qlex as a lifeline to hold onto market share. The subcutaneous delivery technology itself was years in the making, involving a partnership to secure a key enzyme for large-volume injections. The company's yearslong journey to develop Qlex underscores the complexity and cost of such defensive maneuvers. While Qlex will undoubtedly provide a critical revenue bridge, it is a tactical play. The ultimate bet for the $70 billion target remains the successful launch and commercialization of the next wave of pipeline assets. Qlex buys time, but it does not replace the need for new growth.

RVMD as a Strategic Growth Engine: The Revolution Medicines Detour

Merck's pursuit of Revolution Medicines underscores a deliberate strategic intent: to build a diversified portfolio beyond oncology. The deal talks, which briefly dangled a valuation of around $30 billion, were a clear signal of interest in Revolution's leadership in renal-vascular-metabolic disease (RVMD) and RAS-focused oncology. By ending discussions after failing to align on price, Merck cooled immediate speculation but did not extinguish its long-term interest. The door remains open, particularly as Revolution prepares to release closely watched clinical readouts on its cancer candidates in the first half of this year.

This episode highlights the high potential of the RVMD space as a non-oncology growth frontier. Revolution Medicines is developing a pipeline targeting conditions like chronic kidney disease and acute kidney injury, areas with significant unmet medical need. For Merck, acquiring such a focused asset would have been a direct lever to accelerate its diversification, offsetting the softness in its Gardasil vaccine franchise and building a new pillar of revenue. The fact that Revolution's market value has since risen to more than $22 billion demonstrates the market's own re-rating of this strategic niche.

The strategic logic is clear. As Merck navigates the Keytruda cliff, it must cultivate multiple growth vectors. While its recent $10.8 billion acquisition of Verona Pharma bolsters its cardio-pulmonary portfolio, the RVMD area represents a distinct, high-potential domain. The failed Revolution Medicines overture is not a retreat from diversification; it is a tactical pause. It signals that Merck is willing to pay a premium for transformative assets in adjacent therapeutic areas, but only at a price that aligns with its disciplined capital allocation. The upcoming clinical data from Revolution could very well rekindle the company's interest or attract other suitors, keeping the RVMD portfolio a key part of Merck's forward-looking growth narrative.

Pipeline & Portfolio Expansion: The $10 Billion Verona Acquisition

Merck's acquisition of Verona Pharma for approximately $10 billion is a decisive step in its science-led strategy to rapidly build a diversified portfolio. The deal adds Ohtuvayre (ensifentrine), a first-in-class inhaled treatment for chronic obstructive pulmonary disease (COPD), to its pipeline. Approved by the FDA in June 2024 and launched in August, Ohtuvayre is the first novel inhaled mechanism for COPD in over two decades. This acquisition directly expands Merck's cardio-pulmonary franchise, a key area for growth outside of oncology.

The strategic alignment is clear. The purchase fits Merck's broader goal of cultivating multiple growth vectors to offset the Keytruda cliff. By acquiring a commercialized asset with rapid uptake, Merck gains near-term revenue while also securing a pipeline asset for future expansion. CEO Rob Davis framed the deal as a commitment to delivering innovative treatments and executing on a value-driven business development strategy. The move signals that Merck is willing to make large, transformative purchases to accelerate its diversification, a theme also seen in its pursuit of Revolution Medicines.

This acquisition is part of a larger portfolio expansion that feeds directly into the $70 billion target. Ohtuvayre itself is one of the ten key assets identified as contributing to that goal. The pipeline now includes other promising candidates in high-growth non-oncology areas. Winrevair, for instance, is being developed for pulmonary hypertension, while Enlicitide decanoate-a first-in-class oral PCSK9 inhibitor for hypercholesterolemia-has shown statistically significant LDL-C reductions in Phase 3 trials. These assets represent distinct therapeutic avenues with blockbuster potential, each contributing to the structural resilience Merck is building.

The Verona Pharma deal, therefore, is more than a simple add-on. It is a calculated bet on the long-term value of science-led expansion into high-need, high-growth disease areas. By securing Ohtuvayre and its pipeline, Merck is not only filling a gap in its portfolio but also demonstrating the disciplined capital allocation required to achieve its ambitious forward-looking target. The acquisition provides a tangible foundation for growth that extends well beyond the oncology domain.

Catalysts, Scenarios, and What to Watch

The path to a $70 billion commercial opportunity is paved with specific, near-term milestones. Success hinges on validating the clinical and commercial potential of its pipeline, starting with the most immediate catalysts.

The first major test arrives in the first half of this year. Revolution Medicines is preparing to release closely watched clinical readouts on its cancer candidates. These results are critical for Merck, as they could rekindle interest in a potential deal for the RAS-focused biotech. More broadly, they will signal whether the science behind the next wave of oncology assets is robust enough to support the company's growth thesis. Positive data here would not only advance a key pipeline candidate but also reinforce the credibility of Merck's internal development engine.

Beyond these specific readouts, the company's broader pipeline progress is under the microscope. The continued advancement of its 80 Phase III studies is a baseline requirement. Each successful trial completion brings an asset closer to regulatory approval and, ultimately, commercialization. The timeline is tight; the $70 billion target requires the successful launch and scaling of multiple complex assets over the next four years. Any significant delay or setback in this pipeline would directly threaten the forward-looking narrative.

The primary risk is execution. The target is not a passive projection but a demand for flawless commercialization. It demands that Merck not only bring drugs to market but also capture meaningful market share in competitive, high-unmet-need areas. This is where the company's first major non-oncology launches become critical watchpoints. The commercial traction of Winrevair for pulmonary hypertension and Enlicitide decanoate for hypercholesterolemia will be decisive. These are Merck's first major bets in these high-value therapeutic areas, and their performance will validate the company's diversification strategy. Positive early adoption and sales growth for these assets would provide tangible evidence that the pipeline is translating into the revenue growth needed to offset the Keytruda cliff.

In short, the coming months will separate signal from noise. The catalysts are clear: clinical data from Revolution Medicines, continued Phase III progress, and the initial commercial performance of Winrevair and Enlicitide. For investors, the setup is straightforward. Watch these milestones closely; they are the checkpoints that will determine whether Merck's ambitious pivot succeeds or falters.